TARRYTOWN, NY, USA I April 4, 2016 I PGI Drug Discovery LLC (PsychoGenics), today announced that a compound identified through its drug discovery collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) has achieved a milestone.
The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for SEP-856 suggest that it may have the potential to treat the negative symptoms of schizophrenia.
In August 2007, PsychoGenics and Sunovion entered into a drug discovery agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. Using its proprietary in vivo drug discovery technologies, including its SmartCube® system, PsychoGenics evaluated a library of Sunovion compounds, leading to the discovery of several new drug candidates with novel modes of action, including SEP-856.
“Our collaboration with Sunovion is highly productive and rewarding as we interact with some of the best minds and creative scientists in drug discovery. There also are several earlier-stage programs for other CNS indications in Sunovion’s pipeline that further validate our phenotypic approach to CNS drug discovery,” remarked Emer Leahy, Ph.D., PsychoGenics’ President & CEO.
PsychoGenics’ SmartCube®, NeuroCube® and PhenoCube® drug discovery platforms combine broad in vivo behavioral expertise with developments in robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of CNS disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds and compounds with novel mechanisms of action.
About PsychoGenics
PsychoGenics is a leader in in vivo phenotypic drug discovery. The Company’s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology and microdialysis. Complementing its extensive capabilities, the company has a variety of mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high through-put, high content phenotyping and its drug discovery platforms SmartCube®, NeuroCube® and PhenoCube® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and has resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.
SOURCE: PsychoGenics
Post Views: 92
TARRYTOWN, NY, USA I April 4, 2016 I PGI Drug Discovery LLC (PsychoGenics), today announced that a compound identified through its drug discovery collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) has achieved a milestone.
The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for SEP-856 suggest that it may have the potential to treat the negative symptoms of schizophrenia.
In August 2007, PsychoGenics and Sunovion entered into a drug discovery agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. Using its proprietary in vivo drug discovery technologies, including its SmartCube® system, PsychoGenics evaluated a library of Sunovion compounds, leading to the discovery of several new drug candidates with novel modes of action, including SEP-856.
“Our collaboration with Sunovion is highly productive and rewarding as we interact with some of the best minds and creative scientists in drug discovery. There also are several earlier-stage programs for other CNS indications in Sunovion’s pipeline that further validate our phenotypic approach to CNS drug discovery,” remarked Emer Leahy, Ph.D., PsychoGenics’ President & CEO.
PsychoGenics’ SmartCube®, NeuroCube® and PhenoCube® drug discovery platforms combine broad in vivo behavioral expertise with developments in robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of CNS disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds and compounds with novel mechanisms of action.
About PsychoGenics
PsychoGenics is a leader in in vivo phenotypic drug discovery. The Company’s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology and microdialysis. Complementing its extensive capabilities, the company has a variety of mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high through-put, high content phenotyping and its drug discovery platforms SmartCube®, NeuroCube® and PhenoCube® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and has resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.
SOURCE: PsychoGenics
Post Views: 92
